Giovanni Battista Pajno

Dr. Giovanni Battista Pajno

Dept Human Pathol Adulthood & Childhood, University of Messina, Messina, Italy

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2019 in Allergy
Verified
Journal Article
Closed access
PDF file
PMPaolo Maria Matricardi
Paolo Maria Matricardi
SDStephanie Dramburg
Stephanie Dramburg
AAAlberto Alvarez‐Perea
Alberto Alvarez‐Perea
DADarío Antolín-Amérigo2
Darío Antolín-Amérigo2
CAChristian Apfelbacher
Christian Apfelbacher
IAIoana Agache
Ioana Agache

1 January 2012 in Clinical and Translational Allergy
Verified
Journal Article
Open access
PDF file
MCMoises A Calderon
Moises A Calderon
PDPascal Demoly
Pascal Demoly
RWRoy Gerth van Wijk
Roy Gerth van Wijk
Jean BousquetJean Bousquet
Jean Bousquet
ASAziz Sheikh
Aziz Sheikh
NPNikolaos Papadopoulos
Nikolaos Papadopoulos
Allergy today is a public health concern of pandemic proportions, affecting more than 150 million people in Europe alone. In view of epidemiological trends, the European Academy of Allergy and Clinical Immunology (EAACI) predicts that within the next few decades, more than half of the European population may at some point in their lives experience some type of allergy.Not only do allergic patients suffer from a debilitating disease, with the potential for major impact on their quality of life, career progression, personal development and lifestyle choices, but they also constitute a significant burden on health economics and macroeconomics due to the days of lost productivity and underperformance. Given that allergy triggers, including urbanization, industrialization, pollution and climate change, are not expected to change in the foreseeable future, it is imperative that steps are taken to develop, strengthen and optimize preventive and treatment strategies.Allergen specific immunotherapy is the only currently available medical intervention that has the potential to affect the natural course of the disease. Years of basic science research, clinical trials, and systematic reviews and meta‐analyses have convincingly shown that allergen specific immunotherapy can achieve substantial results for patients, improving the allergic individuals’ quality of life, reducing the long‐term costs and burden of allergies, and changing the course of the disease. Allergen specific immunotherapy not only effectively alleviates allergy symptoms, but it has a long‐term effect after conclusion of the treatment and can prevent the progression of allergic diseases.Unfortunately, allergen specific immunotherapy has not yet received adequate attention from European institutions, including research funding bodies, even though this could be a most rewarding field in terms of return on investments, translational value and European integration and, a field in which Europe is recognized as a worldwide leader. Evaluation and surveillance of the full cost of allergic diseases is still lacking and further progress is being stifled by the variety of health systems across Europe. This means that the general population remains unaware of the potential use of allergen specific immunotherapy and its potential benefits.We call upon Europe's policy‐makers to coordinate actions and improve individual and public health in allergy by: Promoting awareness of the effectiveness of allergen specific immunotherapy Updating national healthcare policies to support allergen specific immunotherapy Prioritising funding for allergen specific immunotherapy research Monitoring the macroeconomic and health economic parameters of allergy Reinforcing allergy teaching in medical disciplines and specialties The effective implementation of the above policies has the potential for a major positive impact on European health and well‐being in the next decade.

23 January 2017 in Italian Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
A(Allergen-Specific Immunotherapy Panel Of The Italian Society Of Pediatric Allergy And Immunology (Siaip)
Allergen-Specific Immunotherapy Panel Of The Italian Society Of Pediatric Allergy And Immunology (Siaip)
GPGiovanni Battista Pajno
Giovanni Battista Pajno
RBRoberto Bernardini
Roberto Bernardini
DPDIEGO PERONI
DIEGO PERONI
SAStefania Arasi
Stefania Arasi
MDmarzia duse
marzia duse
Allergen-specific immunotherapy (AIT) is currently recognized as a clinically effective treatment for allergic diseases, with a unique disease-modifying effect. AIT was introduced in clinical practice one century ago, and performed in the early years with allergenic extracts of poor quality and definition. After the mechanism of allergic reaction were recognized, the practice of AIT was refined, leading to remarkable improvement in the efficacy and safety profile of the treatment. Currently AIT is accepted and routinely prescribed worldwide for respiratory allergies and hymenoptera venom allergy. Both the subcutaneous (SCIT) and sublingual (SLIT) routes of administration are used in the pediatric population. AIT is recommended in allergic rhinitis/conjunctivitis with/without allergic asthma, with an evidence of specific IgE-sensitization towards clinically relevant inhalant allergens. Long-term studies provided evidence that AIT can also prevent the onset of asthma and of new sensitizations. The favorable response to AIT is strictly linked to adherence to treatment, that lasts 3–5 years. Therefore, several factors should be carefully evaluated before starting this intervention, including the severity of symptoms, pharmacotherapy requirements and children and caregivers’ preference and compliance. In recent years, there have been increasing interest in the role of AIT for the treatment of IgE-associated food allergy and extrinsic atopic dermatitis. A growing body of evidence shows that oral immunotherapy represents a promising treatment option for IgE-associated food allergy. On the contrary, there are still controversies on the effectiveness of AIT for patients with atopic dermatitis. This consensus document was promoted by the Italian Society of Pediatric Allergy and Immunology (SIAIP) to provide evidence-based recommendations on AIT in order to implement and optimize current prescription practices of this treatment for allergic children.

11 August 2005 in Pediatric Allergy and Immunology
Verified
Journal Article
Closed access
PDF file
LCL. Caminiti
L. Caminiti
GPG. Passalacqua
G. Passalacqua
Giuseppe Magazzu'Giuseppe Magazzu'
Giuseppe Magazzu'
FCF. Comisi
F. Comisi
DVD. Vita
D. Vita
GPGiovanni Battista Pajno
Giovanni Battista Pajno

1 April 2010 in Allergy
Verified
Journal Article
Closed access
PDF file
DVD. Vita
D. Vita
LCL. Caminiti
L. Caminiti
Paolo RuggeriPaolo Ruggeri
Paolo Ruggeri
GPGiovanni Battista Pajno
Giovanni Battista Pajno

9 December 2003 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
PDF file
GPGiovanni Battista Pajno
Giovanni Battista Pajno
DVD. Vita
D. Vita
SPS. Parmiani
S. Parmiani
LCL. Caminiti
L. Caminiti
STEFANIA La GruttaSTEFANIA La Grutta
STEFANIA La Grutta
GBG. Barberio
G. Barberio